Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Advances analyze found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://vona455xjv9.wikissl.com/user